Clinical Trial Update: A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating OP0201 as adjunct treatment for acute otitis media in infants and young children; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Otitis Media

Drugs mentioned

• OP0201

Snippet

Sponsor: Novus Therapeutics, Inc | Conditions: Acute Otitis Media | Phase 2 | Status: COMPLETED | Results posted: 2020-08-11